In January and February 2026, Health Canada released the Quarterly Report for Q2 2025-2026 (July through September 2025) and for Q3 2025-2026 (October through December 2025).
These reports provide data on the processing times for pre-market medical device review as compared to service standards. For each class of medical devices, the reports include the number of applications received, the number of licences issued and the percentage of decisions made within performance targets.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and life sciences regulatory law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Health Canada’s modernization of clinical trial framework: notice of interim policy and results from consultation
As we previously reported, Health Canada consulted on the framework for clinical trials, including on the new Clinical Trials Regulations and draft and updated guidance documents. Health Canada has no...Read More -
Health Canada issues new and updated guidance for managing therapeutic product shortages
On October 7, 2026, Health Canada published a new Guide on extending expiration dates of marketed drugs in response to drug shortages (GUI-0500).Read More -
Health Canada provides its quarterly update and PMPRB publishes the 10th edition of the Meds Entry Watch report
On October 15, 2026, Health Canada provided its quarterly update summarizing steps it has taken “to make its regulatory processes more modern and efficient, while maintaining high standards for safety...Read More
